259 related articles for article (PubMed ID: 26058730)
21. Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A.
Dmoszynska A; Kuliczkowski K; Hellmann A; Trelinski J; Kloczko J; Baglin T; Hay C; O'Shaughnessy D; Zawilska K; Makris M; Shaikh-Zaidi R; Gascoigne E; Dash C
Haemophilia; 2011 May; 17(3):456-62. PubMed ID: 21371184
[TBL] [Abstract][Full Text] [Related]
22. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
[TBL] [Abstract][Full Text] [Related]
23. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2016 Sep; 76(13):1281-1291. PubMed ID: 27487799
[TBL] [Abstract][Full Text] [Related]
24. Beriate® P in the treatment of patients with haemophilia A: results of a long-term pharmacovigilance study.
Klamroth R; Holzhauer S; Zimmermann R; Heller C; Kurnik K;
Thromb Res; 2014 Nov; 134 Suppl 1():S16-21. PubMed ID: 24418255
[TBL] [Abstract][Full Text] [Related]
25. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A.
Auerswald G; Thompson AA; Recht M; Brown D; Liesner R; Guzmán-Becerra N; Dyck-Jones J; Ewenstein B; Abbuehl B
Thromb Haemost; 2012 Jun; 107(6):1072-82. PubMed ID: 22476554
[TBL] [Abstract][Full Text] [Related]
26. Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients.
Mathias M; Abashidze M; Abraham A; Belletrutti MJ; Carcao M; Chambost H; Chan AKC; Dubey L; Ducore J; Lambert T; Kavardakova N; Lohade S; Turea V; Wu JKM; Klukowska A
Haemophilia; 2023 Jul; 29(4):1005-1012. PubMed ID: 37335546
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2.
Giangrande P; Abdul Karim F; Nemes L; You CW; Landorph A; Geybels MS; Curry N
J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):5-14. PubMed ID: 32544297
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5.
Šaulytė Trakymienė S; Economou M; Kenet G; Landorph A; Shen C; Kearney S
J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):15-25. PubMed ID: 32940955
[TBL] [Abstract][Full Text] [Related]
29. Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study.
Nagao A; Deguchi A; Nogami K
Hematology; 2024 Dec; 29(1):2316540. PubMed ID: 38376107
[TBL] [Abstract][Full Text] [Related]
30. BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results.
Lalezari S; Reding MT; Pabinger I; Holme PA; Negrier C; Chalasani P; Shin HJ; Wang M; Tseneklidou-Stoeter D; Maas Enriquez M
Haemophilia; 2019 Nov; 25(6):1011-1019. PubMed ID: 31621991
[TBL] [Abstract][Full Text] [Related]
31. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
Klukowska A; Komrska V; Jansen M; Laguna P
Haemophilia; 2011 May; 17(3):399-406. PubMed ID: 21118334
[TBL] [Abstract][Full Text] [Related]
32. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials.
Fischer K; Collins P; Björkman S; Blanchette V; Oh M; Fritsch S; Schroth P; Spotts G; Ewenstein B
Haemophilia; 2011 May; 17(3):433-8. PubMed ID: 21299740
[TBL] [Abstract][Full Text] [Related]
33. Inhibitor development, safety, and efficacy of Advate
Taki M; Fukutake K; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Arai M; Takagi H; Uchikawa H; Engl W; Shirahata A
Int J Hematol; 2019 Jan; 109(1):70-78. PubMed ID: 30043332
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of low-dose prophylaxis of highly purified plasma-derived factor VIII concentrate produced by the National Blood Centre, Thai Red Cross Society.
Chuansumrit A; Sosothikul D; Natesirinilkul R; Lektrakul Y; Charoonruangrit U;
Haemophilia; 2018 Sep; 24(5):e387-e390. PubMed ID: 30117632
[No Abstract] [Full Text] [Related]
35. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
Richards M; Williams M; Chalmers E; Liesner R; Collins P; Vidler V; Hanley J;
Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
[TBL] [Abstract][Full Text] [Related]
36. Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A.
Frampton JE; Wagstaff AJ
Drugs; 2008; 68(6):839-53. PubMed ID: 18416588
[TBL] [Abstract][Full Text] [Related]
37. Half-life extended factor VIII for the treatment of hemophilia A.
Tiede A
J Thromb Haemost; 2015 Jun; 13 Suppl 1():S176-9. PubMed ID: 26149020
[TBL] [Abstract][Full Text] [Related]
38. Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis.
Carcao M; Lambert T; Leissinger C; Escuriola-Ettingshausen C; Santagostino E; Aledort L;
Haemophilia; 2018 Nov; 24(6):845-848. PubMed ID: 29989273
[No Abstract] [Full Text] [Related]
39. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
40. Turoctocog alfa for the treatment of hemophilia a.
Vakil NH; Fujinami N; Martin-Stone S
Pharmacotherapy; 2014 Oct; 34(10):1091-101. PubMed ID: 25052207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
